IN8bio, Inc. (NASDAQ:INAB) Short Interest Update

IN8bio, Inc. (NASDAQ:INAB) was the recipient of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 800,500 shares, a decrease of 78.7% from the February 13th total of 3,760,000 shares. Based on an average daily volume of 5,060,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 1.2% of the shares of the company are sold short.

IN8bio Stock Performance

NASDAQ INAB traded down $0.02 during midday trading on Thursday, hitting $0.23. The company had a trading volume of 1,818,873 shares, compared to its average volume of 6,671,047. IN8bio has a fifty-two week low of $0.22 and a fifty-two week high of $1.74. The stock has a market cap of $18.39 million, a price-to-earnings ratio of -0.30 and a beta of 0.03. The firm has a fifty day simple moving average of $0.28 and a two-hundred day simple moving average of $0.30. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.05.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03. Equities analysts forecast that IN8bio will post -0.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IN8bio

Several institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC boosted its position in shares of IN8bio by 296.7% during the 4th quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock valued at $30,000 after acquiring an additional 86,696 shares in the last quarter. Geode Capital Management LLC boosted its holdings in IN8bio by 56.5% during the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock valued at $133,000 after purchasing an additional 185,919 shares in the last quarter. Sigma Planning Corp grew its stake in shares of IN8bio by 42.0% in the 3rd quarter. Sigma Planning Corp now owns 851,280 shares of the company’s stock valued at $230,000 after purchasing an additional 251,600 shares during the period. Alyeska Investment Group L.P. raised its holdings in shares of IN8bio by 1,064.5% in the 4th quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock worth $1,302,000 after buying an additional 4,628,482 shares in the last quarter. Finally, Franklin Resources Inc. bought a new position in shares of IN8bio during the 4th quarter worth approximately $1,465,000. Institutional investors own 92.05% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of IN8bio in a report on Wednesday, February 12th.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.